Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2019 Oct;41(10):3670-3676.
doi: 10.1002/hed.25891. Epub 2019 Jul 29.

Phase II trial with axitinib in recurrent and/or metastatic salivary gland cancers of the upper aerodigestive tract

Laura D Locati  1 , Stefano Cavalieri  1 , Cristiana Bergamini  1 , Carlo Resteghini  1 , Salvatore Alfieri  1 , Giuseppina Calareso  2 , Paolo Bossi  1 , Federica Perrone  3 , Elena Tamborini  3 , Pasquale Quattrone  4 , Roberta Granata  1 , Donata Galbiati  1 , Francesca Platini  1 , Ester Orlandi  5 , Luigi Mariani  6 , Lisa Licitra  1   7
Affiliations
Clinical Trial

Phase II trial with axitinib in recurrent and/or metastatic salivary gland cancers of the upper aerodigestive tract

Laura D Locati et al. Head Neck. 2019 Oct.

Abstract

Background: Patients with prognosis recurrent/metastatic (R/M) salivary gland carcinomas (SGCs) are poor. Activity of axitinib was demonstrated in adenoid cystic carcinoma (ACC). We tested axitinib in a larger cohort of R/M SGCs including non-ACC.

Methods: Axitinib was administered at 10 mg daily (dose escalation allowed) until progression or unacceptable toxicity. Null hypothesis would be rejected if more than 3 of 26 responses were observed.

Results: Twenty-six patients (50% were male; 6 ACC, 20 non-ACC) were treated. Response rate was 8% (2 partial responses), 13 stable disease (>6 months in 7 patients) and 11 disease progression. Median progression-free survival and overall survival were 5.5 and 26.2 months, respectively. All patients had at least one adverse event: stomatitis (69%), fatigue (58%) and hypertension (54%) were the most frequent.

Conclusions: This trial did not meet its primary endpoint hence axitinib should not be considered for further investigations in SGCs. Safety profile was in line with the scientific literature.

Keywords: adenoid cystic carcinoma; antiangiogenetic; axitinib; salivary gland cancer; tyrosine kinase inhibitor.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

REFERENCES

    1. Carlson ER. Malignant salivary gland tumors. J Oral Maxillofac Surg. 2016;74(12):2340-2341.
    1. WHO. WHO Classification of Head and Neck Tumours-4th Edition. 2017. Geneva, Switzerland: WHO.
    1. Ciccolallo L, Licitra L, Cantu G, Gatta G. Survival from salivary glands adenoid cystic carcinoma in European populations. Oral Oncol. 2009;45(8):669-674.
    1. Alfieri S, Granata R, Bergamini C, et al. Systemic therapy in metastatic salivary gland carcinomas: a pathology-driven paradigm? Oral Oncol. 2017;66:58-63.
    1. Ross JS, Gay LM, Wang K, et al. Comprehensive genomic profiles of metastatic and relapsed salivary gland carcinomas are associated with tumor type and reveal new routes to targeted therapies. Ann Oncol. 2017;28(10):2539-2546.

Publication types

MeSH terms

LinkOut - more resources